S-Space College of Medicine/School of Medicine (의과대학/대학원) Cancer Research Institute (암연구소) Journal Papers (저널논문_암연구소)
Paclitaxel/platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer
- Choi, In Sil; Oh, Do-Youn; Kwon, Jung Hye; Kim, Sang-Il; Park, Sook Ryun; Bak, Ji-Youn; Kim, Jee Hyun; Kim, Dong-Wan; Kim, Young Tae; Kim, Tae-You; Yoo, Chul-Gyu; Kim, Young Whan; Heo, Dae Seog; Bang, Yung-Jue; Sung, Sook-Whan; Park, Charn Il; Kim, Noe Kyeong
- Issue Date
- Oxford University Press
- Japanese Journal of Clinical Oncology, Vol.35 No.1, pp.6-12
- Objective: The objectives of the present study were to assess the efficacy and tolerability of perioiperative paclitaxel/platinum-based chemotherapy and surgery in patients with stage IIIA clinical N2 (cN2) non-small cell lung cancer (NSCLC). Methods: Clinical N2 was defined as either > 15 mm or > 10 mm and multiple nodes on computed tomography (CT) scan. Thirty-four chemotherapy-naive patients with stage IIIA cN2 received preoperative paclitaxel/cisplatin for two cycles and then underwent surgery. The treatment with paclitaxel/carboplatin was repeated for three cycles after the operation. Results: Of the 34 patients, none achieved a complete response (CR) and 22 achieved a partial response (PR), resulting in a response rate of 65%. Among 29 patients (85%) who had received thoracotomy, 25 (74%) underwent complete resection. Two pathological CRs were observed and mediastinal nodes were free of tumor in 21 %. Grade 3-4 toxicity was uncommon and treatment-related mortality was not observed. The median time to progression (TTP) was 12.1 months [95% confidence interval (CI) 8.3-15.9 months] and median overall survival (OS) was 23.6 months (95% CI 17.7-30.2 months). Conclusions: Paclitaxel/platinum-based perioperative chemotherapy and surgery for patients with stage IIIA cN2 NSCLC is effective and well tolerated.
- Files in This Item: There are no files associated with this item.